Skip to main navigation
Skip to search
Skip to main content
Sort by
Medicine and Dentistry
Hearing Impairment
100%
Ototoxicity
89%
Cisplatin
75%
Childhood Cancer
53%
Oncology
45%
Adolescence
43%
Platinum
37%
Chemotherapy
37%
Hearing
34%
Sodium Thiosulfate
26%
Malignant Neoplasm
25%
Prevalence
25%
Cancer Therapy
22%
Germinoma
20%
Adverse Event
19%
Pediatrics
17%
Late Effect
13%
Cancer
11%
Medulloblastoma
11%
Prospective Study
11%
Ganglioneuroblastoma
10%
Blood Brain Barrier
10%
Cancer in Young Adults
10%
Hearing Assessment
10%
Cohort Analysis
10%
Phase I Trials
10%
Central Nervous System
10%
Supportive Care
10%
Intraarterial Drug Administration
10%
DNA Template
10%
N-Acetylcysteine
10%
Intracranial Tumor
10%
Disease Predisposition
10%
Cerebrospinal Fluid Shunting
10%
Carboplatin
10%
Audiometry
10%
Speech Production
8%
Quality of Life
7%
Metastatic Carcinoma
6%
Arm
5%
Keyphrases
Hearing Impairment
39%
Cisplatin-induced Hearing Loss
38%
Sodium Thiosulfate
35%
Ototoxicity
34%
Hearing Loss in children
31%
Children with Cancer
31%
Pediatric
22%
Otoprotection
21%
Distortion Product Otoacoustic Emissions (DPOAEs)
20%
Adolescents with Cancer
20%
Cisplatin
20%
Amifostine
13%
Sodium Diethyldithiocarbamate
13%
Cisplatin-based Chemotherapy
13%
N-acetylcysteine
13%
Cisplatin Ototoxicity
13%
Tinnitus
12%
Late Effects
12%
Pediatric Cancer
12%
Clinical Practice Guidelines
12%
Test Retest
12%
Pediatric Oncology
11%
Young Adult Cancer Survivors
11%
International Society
11%
Childhood Cancer
10%
Phase I Trial
10%
Cancer Guidelines
10%
Blood-brain Barrier Disruption
10%
Difference Curve
10%
Hierarchical Gaussian Process
10%
Cancer Stem Cells
10%
Hematopoietic Stem Cell Transplantation
10%
Patient-reported Measures
10%
Prediction Model
10%
Novel Prediction
10%
Bone Conduction
10%
Cranial Orthosis
10%
Headband
10%
Disulfiram
10%
Otoacoustic Emission Test
10%
Long-term Variation
10%
Phase 3 Trial
10%
Ototoxicity Monitoring
10%
Digital Technology Application
10%
New International
10%
Consensus Review
10%
Germ Cell Tumor
10%
Global Template
10%
Control Phase
10%
Boston
10%
Nursing and Health Professions
Hearing Impairment
85%
Ototoxicity
77%
Cisplatin
51%
Pediatrics
50%
Chemotherapy
46%
Platinum
39%
Youth
39%
Malignant Neoplasm
29%
Childhood Cancer
28%
Sodium Thiosulfate
19%
Economic and Social Development
18%
Cancer Therapy
15%
Logopedics
15%
Prevalence
14%
Systematic Review
13%
Practice Guideline
13%
Medulloblastoma
13%
Quality of Life
12%
Pilot Study
12%
Tinnitus
11%
Adverse Event
11%
Germ Cell Tumor
10%
Cerebrospinal Fluid Shunting
10%
Hematopoietic Stem Cell Transplantation
10%
Bone Anchored Hearing Aid
10%
Cranial Orthosis
10%
Digitization
10%
Distortion Product Otoacoustic Emission
10%
Cohort Analysis
10%
Audiometry
9%
Pediatrics Patient
6%
Audiologist
5%
Efficacy
5%
Patient-Reported Outcome
5%
